Lipid-lowering treatment in peripheral artery disease

Current Opinion in Pharmacology

Volumn 39, Issue , 2018, Pages 19-26

  Katsiki, Niki ^a   Giannoukas, Athanasios D ^b   Athyros, Vasilios G ^a   Mikhailidis, Dimitri P ^c  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF THESSALY   (Greece)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALIROCUMAB; ANACETRAPIB; ANTILIPEMIC AGENT; ATORVASTATIN; BEZAFIBRATE; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DALCETRAPIB; EVACETRAPIB; EVOLOCUMAB; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; PROPROTEIN CONVERTASE 9 INHIBITOR; ROSUVASTATIN; SERINE PROTEINASE INHIBITOR; SIMVASTATIN; TORCETRAPIB; UNCLASSIFIED DRUG; CETP PROTEIN, HUMAN; CHOLESTEROL ESTER TRANSFER PROTEIN; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9;

CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; COMORBIDITY; CRITICAL LIMB ISCHEMIA; EUROPEAN MEDICINES AGENCY; FOOD AND DRUG ADMINISTRATION; HUMAN; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OUTCOME ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS;

ANIMALS; CHOLESTEROL ESTER TRANSFER PROTEINS; EZETIMIBE; FIBRIC ACIDS; HUMANS; HYPOLIPIDEMIC AGENTS; NIACIN; PERIPHERAL ARTERIAL DISEASE; PROPROTEIN CONVERTASE 9;

EID: 85041696307     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2018.01.003     Document Type: Review

References (129)

1. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285 (2001), 2486–2497.
2. Subherwal, S., Patel, M.R., Kober, L., Peterson, E.D., Bhatt, D.L., Gislason, G.H., Olsen, A.M., Jones, W.S., Torp-Pedersen, C., Fosbol, E.L., Peripheral artery disease is a coronary heart disease risk equivalent among both men and women: results from a nationwide study. Eur J Prev Cardiol 22 (2015), 317–325.
3. Sigvant, B., Lundin, F., Wahlberg, E., The risk of disease progression in peripheral arterial disease is higher than expected: a meta-analysis of mortality and disease progression in peripheral arterial disease. Eur J Vasc Endovasc Surg 51 (2016), 395–403 A recent meta-analysis on the disease progression of PAD.
4. Olin, J.W., Sealove, B.A., Peripheral artery disease: current insight into the disease and its diagnosis and management. Mayo Clin Proc 85 (2010), 678–692.
5. Poussa, H., Strandberg, T.E., Tikkanen, I., Kauhanen, P., Lepäntalo, M., Diagnosis and treatment of dyslipidemia are neglected in patients with peripheral artery disease. Scand Cardiovasc J 41 (2007), 138–141.
6. Howard, D.P., Banerjee, A., Fairhead, J.F., Hands, L., Silver, L.E., Rothwell, P.M., Oxford vascular study: population-based study of incidence, risk factors, outcome, and prognosis of ischemic peripheral arterial events: implications for prevention. Circulation 132 (2015), 1805–1815.
7. Banerjee, A., Fowkes, F.G., Rothwell, P.M., Associations between peripheral artery disease and ischemic stroke: implications for primary and secondary prevention. Stroke 41 (2010), 2102–2107.
8. Takagi, H., Umemoto, T., ALICE (All-Literature Investigation of Cardiovascular Evidence) group: association of peripheral artery disease with abdominal aortic aneurysm growth. J Vasc Surg 64 (2016), 506–513.
9. Long, T.H., Criqui, M.H., Vasilevskis, E.E., Denenberg, J.O., Klauber, M.R., Fronek, A., The correlation between the severity of peripheral arterial disease and carotid occlusive disease. Vasc Med 4 (1999), 135–142.
10. Leertouwer, T.C., Pattynama, P.M., van den Berg-Huysmans, A., Incidental renal artery stenosis in peripheral vascular disease: a case for treatment?. Kidney Int 59 (2001), 1480–1483.
11. Zou, Y., Li, X., Wang, C., Wang, J., Wang, F., Ma, L., You, W., Li, C., Association between non-alcoholic fatty liver disease and peripheral artery disease in patients with type 2 diabetes. Intern Med J 47 (2017), 1147–1153.
12. Garg, P.K., Biggs, M.L., Carnethon, M., Ix, J.H., Criqui, M.H., Britton, K.A., Djoussé L., Sutton-Tyrrell, K., Newman, A.B., et al. Metabolic syndrome and risk of incident peripheral artery disease: the cardiovascular health study. Hypertension 63 (2014), 413–419.
13. Garimella, P.S., Hirsch, A.T., Peripheral artery disease and chronic kidney disease: clinical synergy to improve outcomes. Adv Chronic Kidney Dis 21 (2014), 460–471.
14. Katsiki, N., Athyros, V.G., Karagiannis, A., Mikhailidis, D.P., Characteristics other than the diagnostic criteria associated with metabolic syndrome: an overview. Curr Vasc Pharmacol 12 (2014), 627–641.
15. Katsiki, N., Mikhailidis, D.P., Mantzoros, C.S., Non-alcoholic fatty liver disease and dyslipidemia: an update. Metabolism 65 (2016), 1109–1123.
16. Athyros, V.G., Katsiki, N., Karagiannis, A., Mikhailidis, D.P., Editorial: should chronic kidney disease be considered as a coronary heart disease equivalent?. Curr Vasc Pharmacol 10 (2012), 374–377.
17. Athyros, V.G., Tziomalos, K., Katsiki, N., Doumas, M., Karagiannis, A., Mikhailidis, D.P., Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: an update. World J Gastroenterol 21 (2015), 6820–6834.
18. Katsiki, N., Athyros, V.G., Karagiannis, A., Wierzbicki, A.S., Mikhailidis, D.P., Should we expand the concept of coronary heart disease equivalents?. Curr Opin Cardiol 29 (2014), 389–395.
19. Gerhard-Herman, M.D., Gornik, H.L., Barrett, C., Barshes, N.R., Corriere, M.A., Drachman, D.E., Fleisher, L.A., Fowkes, F.G., Hamburg, N.M., Kinlay, S., et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation 135 (2017), e686–e725 Current guidelines for PAD management by ACC/AHA.
20. Clementi, A., Kim, J.C., Floris, M., Cruz, D.N., Garzotto, F., Zanella, M., Nalesso, F., Brendolan, A., Giavarina, D., Soffiati, G., et al. Statin therapy is associated with decreased small, dense low-density lipoprotein levels in patients undergoing peritoneal dialysis. Contrib Nephrol 178 (2012), 111–115.
21. Rizos, C.V., Kostapanos, M.S., Rizos, E.C., Tselepis, A.D., Elisaf, M.S., The effect of rosuvastatin on low-density lipoprotein subfractions in patients with impaired fasting glucose. J Cardiovasc Pharmacol Ther 20 (2015), 276–283.
22. Gomaraschi, M., Adorni, M.P., Banach, M., Bernini, F., Franceschini, G., Calabresi, L., Effects of established hypolipidemic drugs on HDL concentration, subclass distribution, and function. Handb Exp Pharmacol 224 (2015), 593–615.
23. Mikhailidis, D.P., Elisaf, M., Rizzo, M., Berneis, K., Griffin, B., Zambon, A., Athyros, V., de Graaf, J., März, W., Parhofer, K.G., et al. European panel on low density lipoprotein (LDL) subclasses: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol 9 (2011), 531–532 An expert panel statement on the clinical significance of small dense LDL particles.
24. Otocka-Kmiecik, A., Mikhailidis, D.P., Nicholls, S.J., Davidson, M., Rysz, J., Banach, M., Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?. Prog Lipid Res 51 (2012), 314–324.
25. Chiesa, S.T., Papageorgiou, N., Charakida, M., Statins in peripheral arterial disease. Curr Pharm Des, 2017 September 26 [Epub ahead of print] A recent review on statin use in PAD patients.
26. Kitrou, P., Katsanos, K., Karnabatidis, D., Reppas, L., Brountzos, E., Spiliopoulos, S., Current evidence and future perspectives on anti-platelet and statin pharmacotherapy for patients with symptomatic peripheral arterial disease. Curr Vasc Pharmacol 15 (2017), 430–445.
27. Kumakura, H., Kanai, H., Hojo, Y., Iwasaki, T., Ichikawa, S., Long-term survival and fate of the leg in de novo intermittent claudication. Eur Heart J Qual Care Clin Outcomes 3 (2017), 208–215.
28. Westin, G.G., Armstrong, E.J., Bang, H., Yeo, K.K., Anderson, D., Dawson, D.L., Pevec, W.C., Amsterdam, E.A., Laird, J.R., Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival in patients with critical limb ischemia. J Am Coll Cardiol 63 (2014), 682–690.
29. Suckow, B.D., Kraiss, L.W., Schanzer, A., Stone, D.H., Kalish, J., DeMartino, R.R., Cronenwett, J.L., Goodney, P.P., Vascular Study Group of New England. Statin therapy after infrainguinal bypass surgery for critical limb ischemia is associated with improved 5-year survival. J Vasc Surg 61 (2015), 126–133.
30. Stavroulakis, K., Borowski, M., Torsello, G., Bisdas, T., CRITISCH collaborators: association between statin therapy and amputation-free survival in patients with critical limb ischemia in the CRITISCH registry. J Vasc Surg 66 (2017), 1534–1542 The present study highlights the beneficial effects of statins on limb survival in patients with CLI.
31. Proietti, M., Raparelli, V., Laroche, C., Dan, G.A., Janion, M., Popescu, R., Sinagra, G., Vijgen, J., Boriani, G., Maggioni, A.P., et al., EORP-AF Gen Pilot Investigators. Adverse outcomes in patients with atrial fibrillation and peripheral arterial disease: a report from the EURObservational research programme pilot survey on atrial fibrillation. Europace 19 (2017), 1439–1448.
32. Hsu, C.Y., Chen, Y.T., Su, Y.W., Chang, C.C., Huang, P.H., Lin, S.J., Statin therapy reduces future risk of lower-limb amputation in patients with diabetes and peripheral artery disease. J Clin Endocrinol Metab 102 (2017), 2373–2381.
33. Kumbhani, D.J., Steg, P.G., Cannon, C.P., Eagle, K.A., Smith, S.C. Jr., Goto, S., Ohman, E.M., Elbez, Y., Sritara, P., Baumgartner, I., et al., REACH Registry Investigators. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J 35 (2014), 2864–2872.
34. Vogel, T.R., Dombrovskiy, V.Y., Galiñanes, E.L., Kruse, R.L., Preoperative statins and limb salvage after lower extremity revascularization in the Medicare population. Circ Cardiovasc Interv 6 (2013), 694–700.
35. Klingelhoefer, E., Bergert, H., Kersting, S., Ludwig, S., Weiss, N., Schönleben, F., Grützmann, R., Gäbel, G., Predictive factors for better bypass patency and limb salvage after prosthetic above-knee bypass reconstruction. J Vasc Surg, 64, 2016 380–388.e1.
36. DeCarlo, C., Scher, L., Shariff, S., Phair, J., Lipsitz, E., Garg, K., Statin use and other factors associated with mortality after major lower extremity amputation. J Vasc Surg 66 (2017), 216–225.
37. Harris, S.K., Roos, M.G., Landry, G.J., Statin use in patients with peripheral arterial disease. J Vasc Surg 64 (2016), 1881–1888.
38. Lee, J.H., Ko, Y.G., Shin, D.H., Kim, J.S., Kim, B.K., Choi, D., Hong, M.K., Jang, Y., Attainment of low-density lipoprotein cholesterol goal after endovascular treatment is associated with reduced cardiovascular events in patients with peripheral arterial disease. J Vasc Surg 63 (2016), 756–763 This study supports the achievement of LDL-C goals to improve CV risk in PAD patients.
39. Daskalopoulou, S.S., Daskalopoulos, M.E., Mikhailidis, D.P., Liapis, C.D., Lipid management and peripheral arterial disease. Curr Drug Targets 8 (2007), 561–570.
40. Foley, T.R., Singh, G.D., Kokkinidis, D.G., Choy, H.K., Pham, T., Amsterdam, E.A., Rutledge, J.C., Waldo, S.W., Armstrong, E.J., Laird, J.R., High-intensity statin therapy is associated with improved survival in patients with peripheral artery disease. J Am Heart Assoc, 6, 2017 A review that highlights the importance of high-intensity statin therapy to reduce CV risk and mortality rates in PAD patients.
41. Kim, W., Gandhi, R.T., Peña, C.S., Herrera, R.E., Schernthaner, M.B., Acuña, J.M., Becerra, V.N., Katzen, B.T., The influence of statin therapy on restenosis in patients who underwent nitinol stent implantation for de novo femoropopliteal artery disease: two-year follow-up at a single center. J Vasc Interv Radiol 27 (2016), 1494–1501.
42. Paraskevas, K.I., Giannoukas, A.D., Mikhailidis, D.P., Statins and infrainguinal vascular bypass procedures. Curr Vasc Pharmacol 11 (2013), 51–57 A review that summarizes data on improved perioperative and long-term mortality and morbidity rates in statin-treated PAD patients.
43. Paraskevas, K.I., Athyros, V.G., Briana, D.D., Kakafika, A.I., Karagiannis, A., Mikhailidis, D.P., Statins exert multiple beneficial effects on patients undergoing percutaneous revascularization procedures. Curr Drug Targets 8 (2007), 942–951.
44. Poredos, P., Jezovnik, M.K., Do the effects of secondary prevention of cardiovascular events in PAD patients differ from other atherosclerotic disease?. Int J Mol Sci 16 (2015), 14477–14489.
45. Gargiulo, G., Giugliano, G., Brevetti, L., Sannino, A., Schiattarella, G.G., Serino, F., Carbone, A., Scudiero, F., Ferrone, M., Corrado, R., et al. Use of statins in lower extremity artery disease: a review. BMC Surg, 12, 2012, S15.
46. Meltzer, A.J., Sedrakyan, A., Connolly, P.H., Ellozy, S., Schneider, D.B., Vascular Study Group of Greater New York. Risk factors for suboptimal utilization of statins and antiplatelet therapy in patients undergoing revascularization for symptomatic peripheral arterial disease. Ann Vasc Surg, 2017 June 8 [Epub ahead of print].
47. O'Donnell, T.F.X., Deery, S.E., Darling, J.D., Shean, K.E., Mittleman, M.A., Yee, G.N., Dernbach, M.R., Schermerhorn, M.L., Adherence to lipid management guidelines is associated with lower mortality and major adverse limb events in patients undergoing revascularization for chronic limb-threatening ischemia. J Vasc Surg 66 (2017), 572–578.
48. Argyriou, C., Saleptsis, V., Koutsias, S., Giannoukas, A.D., Peripheral arterial disease is prevalent but underdiagnosed and undertreated in the primary care setting in central Greece. Angiology 64 (2013), 119–124.
49. Steen, D.L., Khan, I., Becker, L., Foody, J.M., Gorcyca, K., Sanchez, R.J., Giugliano, R.P., Patterns and predictors of lipid-lowering therapy in patients with atherosclerotic cardiovascular disease and/or diabetes mellitus in 2014: insights from a large US managed-care population. Clin Cardiol 40 (2017), 155–162.
50. Thiney, M., Della Schiava, N., Feugier, P., Lermusiaux, P., Ninet, J., Millon, A., Long, A., How admission to a vascular surgery department improves medical treatment in patients with lower extremity peripheral arterial disease. Ann Vasc Surg 40 (2017), 85–93.
51. Steenhof, N., Le Piane, F., Leblanc, K., Eisenberg, N.R., Kwan, Y., Malmberg, C., Papadopoulos, A., Roche-Nagle, G., Vascular quality of care pilot study: how admission to a vascular surgery service affects evidence-based pharmacologic risk factor modification in patients with lower extremity peripheral arterial disease. Vasc Health Risk Manag 10 (2014), 333–340.
52. Hussain, M.A., Al-Omran, M., Mamdani, M., Eisenberg, N., Premji, A., Saldanha, L., Wang, X., Verma, S., Lindsay, T.F., Efficacy of a guideline-recommended risk-reduction program to improve cardiovascular and limb outcomes in patients with peripheral arterial disease. JAMA Surg 151 (2016), 742–750.
53. Paraskevas, K.I., Giannoukas, A.D., Mikhailidis, D.P., Renal function impairment in peripheral arterial disease: an important parameter that should not be neglected. Ann Vasc Surg 23 (2009), 690–699.
54. Paraskevas, K.I., Giannoukas, A.D., Mikhailidis, D.P., The impact of impaired renal function on long-term outcomes in patients with peripheral arterial disease. Angiology 61 (2010), 415–416.
55. Nikolic, D., Banach, M., Nikfar, S., Salari, P., Mikhailidis, D.P., Toth, P.P., Abdollahi, M., Ray, K.K., Pencina, M.J., Malyszko, J., et al., Lipid Blood Pressure Meta-Analysis Collaboration Group. A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important?. Int J Cardiol 168 (2013), 5437–5447 A meta-analysis on statin-induced renal benefits in patients with CKD.
56. Alnaeb, M.E., Alobaid, N., Seifalian, A.M., Mikhailidis, D.P., Hamilton, G., Statins and peripheral arterial disease: potential mechanisms and clinical benefits. Ann Vasc Surg 20 (2006), 696–705.
57. Katsiki, N., Athyros, V.G., Karagiannis, A., Mikhailidis, D.P., The role of statins in the treatment of type 2 diabetes mellitus: an update. Curr Pharm Des 20 (2014), 3665–3674.
58. Athyros, V.G., Katsiki, N., Karagiannis, A., Mikhailidis, D.P., Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?. Expert Opin Pharmacother 16 (2015), 1449–1461.
59. Athyros, V.G., Mikhailidis, D.P., Liberopoulos, E.N., Kakafika, A.I., Karagiannis, A., Papageorgiou, A.A., Tziomalos, K., Ganotakis, E.S., Elisaf, M., Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 22 (2007), 118–127.
60. Baigent, C., Landray, M.J., Reith, C., Emberson, J., Wheeler, D.C., Tomson, C., Wanner, C., Krane, V., Cass, A., Craig, J., et al., SHARP Investigators, The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377 (2011), 2181–2192.
61. Briasoulis, A., Pala, M., Telila, T., Merid, O., Akintoye, E., Vogiatzi, G., Oikonomou, E., Tousoulis, D., Statins and contrast-induced nephropathy: a systematic review and meta-analysis. Curr Pharm Des, 2017 September 13 [Epub ahead of print] A recent meta-analysis on the protective role of statins against CI-AKI.
62. Wang, N., Qian, P., Yan, T.D., Phan, K., Periprocedural effects of statins on the incidence of contrast-induced acute kidney injury: a systematic review and trial sequential analysis. Int J Cardiol 206 (2016), 143–152.
63. Katsiki, N., Athyros, V.G., Karagiannis, A., Mikhailidis, D.P., Contrast-induced nephropathy: an “all or none” phenomenon?. Angiology 66 (2015), 508–513.
64. Bragg, D.A., Walling, A., Metabolic syndrome: hyperlipidemia. FP Essent 435 (2015), 17–23.
65. Athyros, V.G., Alexandrides, T.K., Bilianou, H., Cholongitas, E., Doumas, M., Ganotakis, E.S., Goudevenos, J., Elisaf, M.S., Germanidis, G., Giouleme, O., et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism 71 (2017), 17–32 A recent expert panel statement on the use of statins in NAFLD patients.
66. Khavandi, M., Duarte, F., Ginsberg, H.N., Reyes-Soffer, G., Treatment of dyslipidemias to prevent cardiovascular disease in patients with type 2 diabetes. Curr Cardiol Rep, 19, 2017, 7.
67. Katsiki, N., Purrello, F., Tsioufis, C., Mikhailidis, D.P., Cardiovascular disease prevention strategies for type 2 diabetes mellitus. Expert Opin Pharmacother 18 (2017), 1243–1260.
68. Gray, C., Goodman, P., Cullen, P., Badger, S.A., O'Malley, K., O'Donohoe, M.K., McDonnell, C.O., Screening for peripheral arterial disease and carotid artery disease in patients with abdominal aortic aneurysm. Angiology 67 (2016), 346–349.
69. Paraskevas, K.I., Mikhailidis, D.P., Giannoukas, A.D., Additional issues on screening, prevention, and treatment of abdominal aortic aneurysms. Am J Mens Health 7 (2013), 472–474.
70. Weiss, N., Rodionov, R.N., Mahlmann, A., Medical management of abdominal aortic aneurysms. VASA 43 (2014), 415–421.
71. Dunne, J.A., Bailey, M.A., Griffin, K.J., Sohrabi, S., Coughlin, P.A., Scott, D.J., Statins: the holy grail of Abdominal Aortic Aneurysm (AAA) growth attenuation? A systematic review of the literature. Curr Vasc Pharmacol 12 (2014), 168–172.
72. Vlachopoulos, C., Ioakeimidis, N., Aznaouridis, K., Lazaros, G., Tousoulis, D., Statins in diabetes mellitus. Curr Pharm Des, 2017 August 15 [Epub ahead of print].
73. Betteridge, D.J., Carmena, R., The diabetogenic action of statins – mechanisms and clinical implications. Nat Rev Endocrinol 12 (2016), 99–110.
74. Chrysant, S.G., New onset diabetes mellitus induced by statins: current evidence. Postgrad Med 129 (2017), 430–435.
75. Katsiki, N., Rizzo, M., Mikhailidis, D.P., Mantzoros, C.S., New-onset diabetes and statins: throw the bath water out, but, please, keep the baby!. Metabolism 64 (2015), 471–475.
76. Banach, M., Malodobra-Mazur, M., Gluba, A., Katsiki, N., Rysz, J., Dobrzyn, A., Statin therapy and new-onset diabetes: molecular mechanisms and clinical relevance. Curr Pharm Des 19 (2013), 4904–4912.
77. Katsiki, N., Theocharidou, E., Karagiannis, A., Athyros, V.G., Mikhailidis, D.P., Ezetimibe therapy for dyslipidemia: an update. Curr Pharm Des 19 (2013), 3107–3114 A review summarizing the beneficial effects of ezetimibe as a lipid-lowering drug.
78. Winkler, K., Jacob, S., Müller-Schewe, T., Hoffmann, M.M., Konrad, T., Ezetimibe alone and in combination lowers the concentration of small, dense low-density lipoproteins in type 2 diabetes mellitus. Atherosclerosis 220 (2012), 189–193.
79. Simon, T.G., Corey, K.E., Chung, R.T., Giugliano, R., Cardiovascular risk reduction in patients with nonalcoholic fatty liver disease: the potential role of ezetimibe. Dig Dis Sci 61 (2016), 3425–3435.
80. Iqbal, J., Al Qarni, A., Hawwari, A., Al Ghanem, A.F., Gasmelseed, A., Metabolic syndrome, dyslipidemia and regulation of lipoprotein metabolism. Curr Diabetes Rev, 2017 July 5 [Epub ahead of print].
81. Katsiki, N., Tentolouris, N., Mikhailidis, D.P., Dyslipidaemia in type 2 diabetes mellitus: bad for the heart. Curr Opin Cardiol 32 (2017), 422–429.
82. Katsiki, N., Athyros, V.G., Karagiannis, A., Exploring the management of statin intolerant patients: 2016 and beyond. Curr Vasc Pharmacol 14 (2016), 523–533.
83. Cannon, C.P., Blazing, M.A., Giugliano, R.P., McCagg, A., White, J.A., Theroux, P., Darius, H., Lewis, B.S., Ophuis, T.O., Jukema, J.W., et al., IMPROVE-IT Investigators, Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372 (2015), 2387–2397.
84. http://care.diabetesjournals.org/content/diacare/suppl/2016/12/15/40.Supplement_1.DC1/DC_40_S1_final.pdf.
85. West, A.M., Anderson, J.D., Meyer, C.H., Epstein, F.H., Wang, H., Hagspiel, K.D., Berr, S.S., Harthun, N.L., DiMaria, J.M., Hunter, J.R., et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis 218 (2011), 156–162.
86. Brunner, G., Yang, E.Y., Kumar, A., Sun, W., Virani, S.S., Negi, S.I., Murray, T., Lin, P.H., Hoogeveen, R.C., Chen, C., et al. The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT). Atherosclerosis 231 (2013), 371–377.
87. West, A.M., Anderson, J.D., Epstein, F.H., Meyer, C.H., Wang, H., Hagspiel, K.D., Berr, S.S., Harthun, N.L., Weltman, A.L., Dimaria, J.M., et al. Low-density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease. J Am Coll Cardiol 58 (2011), 1068–1076.
88. Katsiki, N., Nikolic, D., Montalto, G., Banach, M., Mikhailidis, D.P., Rizzo, M., The role of fibrate treatment in dyslipidemia: an overview. Curr Pharm Des 19 (2013), 3124–3131.
89. Kushner, P.A., Cobble, M.E., Hypertriglyceridemia: the importance of identifying patients at risk. Postgrad Med 128 (2016), 848–858.
90. Gandhi, N., Lenton, R., Bhartia, M., Abbas, A., Raju, J., Ramachandran, S., Effect of fibrate treatment on liver function tests in patients with the metabolic syndrome. Springerplus, 3, 2014, 14.
91. ACCORD Study Group, Ginsberg, H.N., Elam, M.B., Lovato, L.C., Crouse, J.R. 3rd, Leiter, L.A., Linz, P., Friedewald, W.T., Buse, J.B., Gerstein, H.C., Probstfield, J., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362 (2010), 1563–1574.
92. Elam, M.B., Ginsberg, H.N., Lovato, L.C., Corson, M., Largay, J., Leiter, L.A., Lopez, C., O'Connor, P.J., Sweeney, M.E., Weiss, D., et al., ACCORDION Study Investigators. Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. JAMA Cardiol 2 (2017), 370–380.
93. Keech, A., Simes, R.J., Barter, P., Best, J., Scott, R., Taskinen, M.R., Forder, P., Pillai, A., Davis, T., Glasziou, P., et al., FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005), 1849–1861.
94. Rajamani, K., Colman, P.G., Li, L.P., Best, J.D., Voysey, M., D'Emden, M.C., Laakso, M., Baker, J.R., Keech, A.C., FIELD Study Investigators. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 373 (2009), 1780–1788.
95. Jun, M., Zhu, B., Tonelli, M., Jardine, M.J., Patel, A., Neal, B., Liyanage, T., Keech, A., Cass, A., Perkovic, V., Effects of fibrates in kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol 60 (2012), 2061–2071.
96. Sica, D.A., Fibrate therapy and renal function. Curr Atheroscler Rep 11 (2009), 338–3342.
97. Pollak, A.W., Kramer, C.M., LDL lowering in peripheral arterial disease: are there benefits beyond reducing cardiovascular morbidity and mortality?. Clin Lipidol 7 (2012), 141–149.
98. Meade, T., Zuhrie, R., Cook, C., Cooper, J., Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ, 325, 2002, 1139.
99. Katsiki, N., Athyros, V.G., Karagiannis, A., Mikhailidis, D.P., High-density lipoprotein, vascular risk, cancer and infection: a case of quantity and quality?. Curr Med Chem 21 (2014), 2917–2926.
100. AIM-HIGH Investigators, Boden, W.E., Probstfield, J.L., Anderson, T., Chaitman, B.R., Desvignes-Nickens, P., Koprowicz, K., McBride, R., Teo, K., Weintraub, W., Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365 (2011), 2255–2267.
101. HPS2-THRIVE Collaborative Group, Landray, M.J., Haynes, R., Hopewell, J.C., Parish, S., Aung, T., Tomson, J., Wallendszus, K., Craig, M., Jiang, L., Collins, R., et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 371 (2014), 203–212.
102. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/01/news_detail_001694.jsp&mid=WC0b01ac058004d5c1.
103. Blankenhorn, D.H., Azen, S.P., Crawford, D.W., Nessim, S.A., Sanmarco, M.E., Selzer, R.H., Shircore, A.M., Wickham, E.C., Effects of colestipol–niacin therapy on human femoral atherosclerosis. Circulation 83 (1991), 438–447.
104. Hiatt, W.R., Hirsch, A.T., Creager, M.A., Rajagopalan, S., Mohler, E.R., Ballantyne, C.M., Regensteiner, J.G., Treat-Jacobson, D., Dale, R.A., Rooke, T., Effect of niacin ER/lovastatin on claudication symptoms in patients with peripheral artery disease. Vasc Med 15 (2010), 171–179.
105. Chesney, C.M., Elam, M.B., Herd, J.A., Davis, K.B., Garg, R., Hunninghake, D., Kennedy, J.W., Applegate, W.B., Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT). Am Heart J 140 (2000), 631–636.
106. Pang, D.K., Nong, Z., Sutherland, B.G., Sawyez, C.G., Robson, D.L., Toma, J., Pickering, J.G., Borradaile, N.M., Niacin promotes revascularization and recovery of limb function in diet-induced obese mice with peripheral ischemia. Pharmacol Res Perspect, 4, 2016, e00233.
107. Mohammadpour, A.H., Akhlaghi, F., Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective. Clin Pharmacokinet 52 (2013), 615–626.
108. Barter, P.J., Caulfield, M., Eriksson, M., Grundy, S.M., Kastelein, J.J., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.C., Waters, D.D., et al., ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357 (2007), 2109–2122.
109. Schwartz, G.G., Olsson, A.G., Abt, M., Ballantyne, C.M., Barter, P.J., Brumm, J., Chaitman, B.R., Holme, I.M., Kallend, D., Leiter, L.A., et al., dal-OUTCOMES Investigators, Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367 (2012), 2089–2099.
110. Lincoff, A.M., Nicholls, S.J., Riesmeyer, J.S., Barter, P.J., Brewer, H.B., Fox, K.A.A., Gibson, C.M., Granger, C., Menon, V., Montalescot, G., et al., ACCELERATE Investigators, Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med 376 (2017), 1933–1942.
111. Kosmas, C.E., DeJesus, E., Rosario, D., Vittorio, T.J., CETP inhibition: past failures and future hopes. Clin Med Insights Cardiol 10 (2016), 37–42.
112. Katsiki, N., Athyros, V.G., Mikhailidis, D.P., The DEFINE study: a bright future for CETP inhibitors?. Expert Opin Investig Drugs 20 (2011), 311–314.
113. https://investor.lilly.com/releasedetail.cfm?releaseid=936130.
114. HPS3/TIMI55-REVEAL Collaborative Group, Bowman, L., Hopewell, J.C., Chen, F., Wallendszus, K., Stevens, W., Collins, R., Wiviott, S.D., Cannon, C.P., Braunwald, E., Sammons, E., et al. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med 377 (2017), 1217–1227.
115. http://investors.merck.com/news/press-release-details/2017/Merck-Provides-Update-on-Anacetrapib-Development-Program/default.aspx.
116. Katsiki, N., Athyros, V.G., Mikhailidis, D.P., Mantzoros, C., Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial. Metabolism 74 (2017), 43–46.
117. Alkindi, M., Siminovitch, K.A., Gupta, M., Genest, J., Monoclonal antibodies for the treatment of hypercholesterolemia: targeting PCSK9. Can J Cardiol 32 (2016), 1552–1560.
118. Ferdinand, K.C., Nasser, S.A., PCSK9 inhibition: discovery, current evidence, and potential effects on LDL-C and Lp(a). Cardiovasc Drugs Ther 29 (2015), 295–308.
119. Robinson, J.G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E.S., Langslet, G., Raal, F.J., El Shahawy, M., et al., ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 372 (2015), 1489–1499.
120. Sabatine, M.S., Giugliano, R.P., Wiviott, S.D., Raal, F.J., Blom, D.J., Robinson, J., Ballantyne, C.M., Somaratne, R., Legg, J., Wasserman, S.M., et al., Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 372 (2015), 1500–1509.
121. Sabatine, M.S., Giugliano, R.P., Keech, A.C., Honarpour, N., Wiviott, S.D., Murphy, S.A., Kuder, J.F., Wang, H., Liu, T., Wasserman, S.M., et al., FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376 (2017), 1713–1722.
122. Sabatine, M.S., Leiter, L.A., Wiviott, S.D., Giugliano, R.P., Deedwania, P., De Ferrari, G.M., Murphy, S.A., Kuder, J.F., Gouni-Berthold, I., Lewis, B.S., et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol, 2017 September 14 [Epub ahead of print].
123. Schwartz, G.G., Bessac, L., Berdan, L.G., Bhatt, D.L., Bittner, V., Diaz, R., Goodman, S.G., Hanotin, C., Harrington, R.A., Jukema, J.W., et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J 168 (2014), 682–689.
124. Schmidt, A.F., Pearce, L.S., Wilkins, J.T., Overington, J.P., Hingorani, A.D., Casas, J.P., PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev, 4, 2017, CD011748.
125. Khan, A.R., Bavishi, C., Riaz, H., Farid, T.A., Khan, S., Atlas, M., Hirsch, G., Ikram, S., Bolli, R., Increased risk of adverse neurocognitive outcomes with proprotein convertase subtilisin-kexin type 9 inhibitors. Circ Cardiovasc Qual Outcomes, 10, 2017.
126. Schulz, R., Schlüter, K.D., PCSK9 targets important for lipid metabolism. Clin Res Cardiol Suppl 12 (2017), 2–11.
127. Katsiki, N., Al-Rasadi, K., Mikhailidis, D.P., Lipoprotein (a) and cardiovascular risk: the show must go on. Curr Med Chem 24 (2017), 989–1006.
128. Alexandrou, A.T., Tsimikas, S., Elevated Lp(a) and abdominal aortic aneurysm. Angiology 68 (2017), 96–98.
129. Kotani, K., Sahebkar, A., Serban, M.C., Ursoniu, S., Mikhailidis, D.P., Mariscalco, G., Jones, S.R., Martin, S., Blaha, M.J., Toth, P.P., et al., Lipid Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Lipoprotein(a) levels in patients with abdominal aortic aneurysm. Angiology 68 (2017), 99–108.